Piscoya J, Rodriguez Z, Bustamante S A, Okuhama N N, Miller M J, Sandoval M
Universidad Nacional Mayor de San Marcos, Facultad de Medicina, Lima, Peru.
Inflamm Res. 2001 Sep;50(9):442-8. doi: 10.1007/PL00000268.
The purpose of this investigation was to evaluate the ability of cat's claw, an Amazonian medicinal plant, to treat osteoarthritis of the knee, collect safety and tolerance information and compare the antioxidant, and anti-inflammatory actions of Uncaria guianensis and Uncaria tomentosa in vitro.
Forty-five patients with osteoarthritis of the knee were recruited, 30 were treated with freeze-dried U guianensis, and 15 with placebo. Hematological parameters were assessed on entry and exit of the four-week trial. Pain, medical and subject assessment scores and adverse effects were collected at weeks 1, 2 and 4. The antioxidant and anti-inflammatory activity of the cat's claw species was determined by the alpha,alpha-diphenyl-beta-picrylhydrazyl (DPPH) free radical scavenging method. Inhibition of TNFalpha and prostaglandin E2 (PGE2) production was determined in RAW 264.7 cells by ELISA.
Cat's claw had no deleterious effects on blood or liver function or other significant side-effects compared to placebo. Pain associated with activity, medical and patient assessment scores were all significantly reduced, with benefits occurring within the first week of therapy. Knee pain at rest or at night, and knee circumference were not significantly reduced by cat's claw during this brief trial. In vitro tests indicated that U guianensis and U. tomentosa were equivalent at quenching DPPH radicals (EC50, 13.6-21.7 microg/ml) as well as inhibiting TNFalpha production. However, the latter action was registered at much lower concentrations (EC50, 10.2-10.9 ng/ml). Cat's claw (10 microg/ml) had no effect on basal PGE2 production, but reduced LPS-induced PGE2 release (P < 0.05), but at higher concentrations than that required for TNFalpha inhibition.
Cat's claw is an effective treatment for osteoarthritis. The species, U guianensis and U tomentosa are equiactive. They are effective antioxidants, but their anti-inflammatory properties may result from their ability to inhibit TNFalpha and to a lesser extent PGE2 production.
本研究旨在评估一种亚马逊药用植物猫爪草治疗膝关节骨关节炎的能力，收集安全性和耐受性信息，并比较圭亚那钩藤和绒毛钩藤在体外的抗氧化和抗炎作用。
招募了45例膝关节骨关节炎患者，其中30例接受冻干的圭亚那钩藤治疗，15例接受安慰剂治疗。在为期四周的试验开始和结束时评估血液学参数。在第1、2和4周收集疼痛、医学和受试者评估评分以及不良反应。通过α，α-二苯基-β-苦基肼（DPPH）自由基清除法测定猫爪草属植物的抗氧化和抗炎活性。通过酶联免疫吸附测定法（ELISA）在RAW 264.7细胞中测定肿瘤坏死因子α（TNFα）和前列腺素E2（PGE2）产生的抑制情况。
与安慰剂相比，猫爪草对血液或肝功能没有有害影响或其他明显的副作用。与活动相关的疼痛、医学和患者评估评分均显著降低，在治疗的第一周内就出现了疗效。在这个简短的试验中，猫爪草并未显著降低静息或夜间的膝关节疼痛以及膝关节周长。体外试验表明，圭亚那钩藤和绒毛钩藤在淬灭DPPH自由基（半数有效浓度[EC50]，13.6 - 21.7微克/毫升）以及抑制TNFα产生方面效果相当。然而，后者的作用在低得多的浓度下（EC50，10.2 - 10.9纳克/毫升）就已显现。猫爪草（10微克/毫升）对基础PGE2的产生没有影响，但可降低脂多糖诱导的PGE2释放（P < 0.05），不过所需浓度高于抑制TNFα所需的浓度。
猫爪草是治疗骨关节炎的有效药物。圭亚那钩藤和绒毛钩藤这两个物种具有同等活性。它们是有效的抗氧化剂，但其抗炎特性可能源于它们抑制TNFα的能力以及在较小程度上抑制PGE2产生的能力。
